Japan Market Access and PASS– a must for launch

Register Free: http://www.pharmexec.com/pe_w/launch

Event overview:

Launching in Japan, the second-largest branded pharmaceutical market, requires an understanding of market access/HTA and Post-Authorization Safety Studies (PASS).

Join IQVIA to gain insights into the key milestones on the roadmap to market access and PASS in Japan.

3 Key Take-aways:

• Must need after approval
• Market Access strategies
• Post-Authorization Safety Studies

In case of any questions, please contact Julia Longo at jlongo@mjhlifesciences.com

Information provided by you is stored on our database and may be used for sending you additional information about IQVIA group services. Such information may be transferred for this purpose to IQVIA companies based in other countries. If you do not wish to receive further information about IQVIA group services please email opt-out@iqvia.com. Copyright © 2022 IQVIA INC and its affiliates. All rights reserved.

Speakers

Sven Demiya PhD, MBA
Principal, HEOR, Real World Evidence Solutions
IQVIA Japan Group

Sven leads the HEOR, Real World Evidence Solutions group based in Tokyo, Japan. He has over 12 years' experience in various pharmaceutical companies in various positions: HEOR, Medical Affairs, Global Clinical Development, and Clinical Pharmacology. Further, he took part in the Human Genome Project analyzing human big data at the RIKEN Institute.

Keiko Asao, MD, PhD
Associate Principal, HEOR, Real World Evidence Solutions
IQVIA Japan Group

Keiko is an epidemiologist with 20+ years of experience in epidemiology, observational research, and real-world evidence in Japan and the United States. Before joining IQVIA, she held positions in Medical Affairs in pharmaceutical companies for medical strategies, evidence generation, and business solutions using real-world data, and practiced internal medicine and endocrinology.

Register Free: http://www.pharmexec.com/pe_w/launch